Recombinant Sars-Cov-2 (COVID-19/2019-nCov) Spike S1 Protein
Fig 1 : Recombinant 2019-nCoV Spike S1 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 130-160 kDa.
Recombinant Sars-Cov-2 (COVID-19/2019-nCov) Spike S1 Protein
Cat# 32-190015-100
Size : 100ug
Brand : Abeomics
Contact local distributor :
Phone : +1 850 650 7790
| Amount : | 100 µg |
| Purification : | >95% by SDS-PAGE. |
| Content : | Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4. |
| Storage condition : | Store the lyophilized protein at -20°C to -80 °C for long term. After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week. |
| AA sequence : | Tag Fc, 6×His tag at the C-terminus. (Val11-Arg682) |
| Gene ID : | 43740568 |
| Alternative Name : | S1 protein,Spike glycoprotein Subunit1,S glycoprotein Subunit1,Spike protein S1,novel coronavirus s1 Protein |
Source: HEK293 cells.
Endotoxin < 1.0 EU/µg of the protein by LAL method.
Recombinant 2019-nCoV Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of 2019-ncov Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6×His tag at the C-terminus.
Reconstitution: Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Biological Activity: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human ACE2 at 2μg/mL (100 μL/well) can bind Recombinant 2019-nCoV Spike S1-TEVS-hFc-His with a linear range of 78-82.5 ng/mL.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.
1. Reiser J1, Wei C2, Datta P3, Siegerist F1, Li J1, Sudhini Y4, Koh K5, Kriho N6, Ismail A1, Luo S2, Fischer T1, Amber K5, Cimbaluk D1, Landay A3, Endlich N2, Rappaport J6, Hayek S1.
Virus-response proteinuria underlies rapid changes in kidney filtration barrier function in COVID-19.
Preprint from Research Square, 23 Mar 2023. DOI: 10.21203/rs.3.rs-2659085/v1
PPR: PPR635107
2. Noviello M, De Lorenzo R, Chimienti R, Maugeri N, De Lalla C, Siracusano G, Lorè NI, Rancoita PMV, Cugnata F, Tassi E, Dispinseri S, Abbati D, Beretta V, Ruggiero E, Manfredi F, Merolla A, Cantarelli E, Tresoldi C, Pastori C, Caccia R, Sironi F, Marzinotto I, Saliu F, Ghezzi S, Lampasona V, Vicenzi E, Cinque P, Manfredi AA, Scarlatti G, Dellabona P, Lopalco L, Di Serio C, Malnati M, Ciceri F, Rovere-Querini P, Bonini C.
The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.
Front Immunol. 2024 Jul 29;15:1381091. doi: 10.3389/fimmu.2024.1381091.
PMID: 39136010; PMCID: PMC11317765.
| There are currently no product reviews |
